Navigation Links
IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
Date:8/24/2009

HOUSTON, Aug. 24 /PRNewswire/ -- IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA). PAD of the lower extremities affects approximately 8 million-12 million people in the U.S. alone, according to the American Heart Association.

The clinical trial, called SUPERB (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery), is a prospective, single-arm trial of 258 patients at up to 40 U.S. sites. It is led by national co-principal investigators Kenneth Rosenfield, M.D., Section Head for Vascular Medicine and Intervention at Massachusetts General Hospital, Boston, and Lawrence A. Garcia, M.D. Chief, Section Interventional Cardiology and Associate Director of Vascular Medicine at Boston's Caritas St. Elizabeth Medical Center, where the first patient was treated.

The objective of the trial is to demonstrate the safety and effectiveness of the SUPERA stent in the treatment of obstructive arterial disease in the superficial femoral artery of the lower extremity. The SUPERA Interwoven Self-Expanding Nitinol Stent Transhepatic Biliary system received 510(k) clearance for palliative treatment of biliary strictures produced by malignant neoplasms and the SUPERA Interwoven Self-Expanding Nitinol Stent System received CE Mark approval in Europe for biliary and peripheral vascular indications.

"The SUPERA stent has unique properties that may be demonstrated on patients at facilities throughout the
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... new survey shows almost half (44%) of U.S. patients ... acute pain. (Logo: http://photos.prnewswire.com/prnh/20110816/DC52192LOGO-b ) ... Pain (P3) Survey, one of the largest pain management ... also show that this undertreatment was particularly prevalent among ...
... 2011 Cohera Medical, Inc.®, a rapidly growing medical ... Mark approval for its lead product, TissuGlu® ... to be sold in the European Union. ... large flap surgeries, such as abdominoplasties, that helps reduce ...
Cached Medicine Technology:New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 3
(Date:4/23/2014)... of scientists led by a researcher from the Cancer ... University of Singapore has identified the cancer specific stem ... the possibility of developing new drugs for the treatment ... The research group, led by Dr Chan Shing Leng, ... first time that a cancer-specific variant of a cell ...
(Date:4/23/2014)... also known as Ritalin, may prevent the depletion of ... , a journal of the Association for Psychological Science. ... diet or trying to focus attention on a boring ... one potential explanation for this difficulty: Exerting self-control for ... exert self-control effectively on subsequent tasks. , "It is ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making ... . , A team of physician-scientists at UT ... (a hormone with natural anti-depressant properties) works inside the ... treatment for depression in the form of a neuroprotective ... published online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... (April 22, 2014) The International Communication Association ... in Seattle, Washington. The theme of the 2014 ... in a networked and digital society. , Featuring ... by over 2,200 Communication scholars representing over 40 ... international communication conference in the world. This year,s ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... ... ... ... ...
... behind many countries in the use of electronic health ... and political leaders set targets for universal adoption, states ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj092189.pdf . ... in federal funds to develop integrated electronic health records, ...
... ... ... ... ...
... ... ... , ... HOUSTON , March 1 Despite Northstar ...
... ... Position , ... Ariz. (Vocus) February 28, 2010 -- Tom Rios has been promoted to Executive Director ... he had been Splendido’s director of accounting., , ,Rios will work with managers and ...
... ... ... ... ...
Cached Medicine News:Health News:Chlorella: A Green Whole Food That Can Help Improve the American Diet 2Health News:Chlorella: A Green Whole Food That Can Help Improve the American Diet 3Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 2Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 3Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 4Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 5Health News:Northstar Management Forecasts a Loss of $1.2 Million for 2010 at Its Palladium for Surgery -- Houston, Ltd. Centre 2Health News:Tom Rios Named Executive Director at Splendido 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: